Use of a yeast assay to detect functional alterations in p53 in prostate cancer: Review and future directions

Prostate

Volumn 41, Issue 2, 1999, Pages 134-142

  DeVere White, Ralph W ^a   Deitch, Arline D ^a   Gumerlock, Paul H ^a   Shi, Xu Bao ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

p53; Prostate cancer; Yeast functional assays

Indexed keywords

ANDROGEN RECEPTOR; CARCINOGEN; LOMUSTINE; PROTEIN P53; TRANSCRIPTION FACTOR;

ASSAY; CANCER GROWTH; GENE MUTATION; GENE THERAPY; HUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; REPRODUCIBILITY; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM; TEMPERATURE DEPENDENCE; TRANSACTIVATION; YEAST;

BIOLOGICAL ASSAY; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MALE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YEASTS;

EID: 0032880528     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19991001)41:2<134::AID-PROS8>3.0.CO;2-E     Document Type: Review

References (69)

1. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J, Tada M, van Meir EG, Estreicher A, Iggo RD. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995;92:3963-3967.
2. Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 1998;58:4023-4037.
3. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1:44-49.
4. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-355.
5. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-1455.
6. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology 1996;48:971-979.
7. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;65:5-27.
8. Chi SG, deVere White RW, Meyers FJ, Siders D, Lee F, Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994;86:926-933.
9. Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, deVere White RW. p53 abnormalities in primary prostate cancer: SSCP analysis of cDNA detects rare mutant transcripts. J Natl Cancer Inst 1997;89:66-71.
10. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993;53:3369-3373.
11. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-1669.
12. Ittmann M, Wieczorek R, Heller P, Dave A, Provet J, Krolewski J, Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol 1994;145:287-293.
13. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1995;1:1111-1118.
14. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, Srivastava S. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995;154:414-421.
15. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 1998;83:2534-2539.
16. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991;51:4716-4720.
17. Shi XB, Bodner SM, deVere White RW, Gumerlock PH. Identification of p53 mutations in archival prostate tumors. Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay. Diagn Mol Pathol 1996;5:271-278.
18. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, Roy-Burman P. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995;147: 92-101.
19. Konishi N, Hiasa Y, Hayashi I, Matsuda H, Tsuzuki T, Ming T, Kitahori Y, Shiraishi T, Yatani R, Shimazaki J. p53 mutations occur in clinical, but not latent, human prostate carcinoma. Jpn J Cancer Res 1995;86:57-63.
20. Kubota Y, Shuin T, Uemura H, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Danenberg K, Danenberg PV. Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 1995;27:18-24.
21. Massenkeil G, Oberhuber H, Hailemariam S, Sulser T, Diener PA, Bannwart F, Schafer R, Schwarte-Waldhoff I. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. Anticancer Res 1994;14:2785-2790.
22. Uchida T, Wada C, Shitara T, Egawa S, Koshiba K. Infrequent involvement of p53 gene mutations in the tumourigenesis of Japanese prostate cancer. Br J Cancer 1993;68:751-755.
23. Voeller HJ, Sugars LY, Pretlow T, Gelmann EP. p53 oncogene mutations in human prostate cancer specimens. J Urol 1994;151: 492-495.
24. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, Chung LW. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 1995;45:470-475.
25. Effert PJ, McCoy RH, Walther PJ, Liu ET. p53 gene alterations in human prostate carcinoma. J Urol 1993;150:257-261.
26. Moyret-Lalle C, Marçais C, Jacquemier J, Moles JP, Daver A, Soret JY, Jeanteur P, Ozturk M, Theillet C. ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 1995;64:124-129.
27. Berthen P, Dimitrov T, Stower M, Cussenot O, Maitland NJ A microdissection approach to detect molecular markers during progression of prostate cancer. Br J Cancer 1995;72:946-951.
28. Kunimi K, Amano T, Uchibayashi T. Point mutation of the p53 gene is an infrequent event in untreated prostate cancer. Cancer Detect Prev 1996;20:218-222.
29. Suzuki H, Komiya A, Aida S, Ito H, Yatani R, Shimazaki J. Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Prostate 1996;28:318-324.
30. Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J Urol 1996;155:1685-1692.
31. Watanabe M, Ushijima T, Kakiuchi H, Shiraishi T, Yatani R, Shimazaki J, Kotake T, Sugimura T, Nagao M. p53 gene mutations in human prostate cancers in Japan: different mutation spectra between Japan and Western countries. Jpn J Cancer Res 1994;85:904-910.
32. Dinjens WN, van der Weiden MM, Schroeder FH, Bosman FT, Trapman J. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 1994;6:630-633.
33. Ishioka C, Frebourg T, Yan YX, Vidai M, Friend SH, Schmidt S, Iggo R. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 1993;5:124-129.
34. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57: 4285-4300.
35. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998;292:435-445.
36. Cai Z, Capoulade C, Moyret-Lalle C, Amor-Gueret M, Feunteun J, Larsen AK, Paillerets BB, Chouaib S. Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. Oncogene 1997;15:2817-2826.
37. deVere White RW, Shi XB, Gumerlock PH. Prostate cancerderived mutant p53 alleles have different levels of transactivational function. Proc Am Assoc Cancer Res 1999;4637 [abstract].
38. Lomax ME, Barnes DM, Gilchrist R, Picksley SM, Varley JM, Camplejohn RS. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. Oncogene 1997;14:1869-1874.
39. Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T, Shimodaira H, Niitani T, Kudo T, Akiyama M, Kimura N, Matsuo M, Mizusavva H, Tanaka N, Koyama H, Namba M, Kanamaru R, Kuroki T. Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 1997;9:243-253.
40. Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 1998;58:698-703.
41. Rand A, Glenn KS, Alvares CP, White MB, Thibodeau SM, Karnes WE Jr. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles. Cancer Lett 1996;98:183-191.
42. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by temperature-sensitive mutant of p53. Cell 1990;62:671-680.
43. Milner J, Medcalf EA. Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135. J Mol Biol 1990;216:481-484.
44. Friedlander P, Prives C, Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 1996;16:4961-71.
45. Ponchel F, Milner J. Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo. Br J Cancer 1998;77:1555-1561.
46. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998;16:3269-3277.
47. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998;292:435-445.
48. Inga A, Cresta S, Monti P, Aprile A, Scott G, Abbondandolo A, Iggo R, Fronza G. Simple identification of dominant p53 mutants by a yeast functional assay. Carcinogenesis 1997;18:2019-2021.
49. Waridel F, Estreicher A, Bron L, Flaman JM, Fontolliet C, Monnier P, Frebourg T, Iggo R. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 1997; 14:163-169.
50. Tada M, Iggo RD, Ishii N, Shinohe Y, Sakuma S, Estreicher A, Sawamura Y, Abe H. Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Int J Cancer 1996;67:447-450.
51. Tada M, Iggo RD, Waridel F, Nozaki M, Matsumoto R, Sawamura Y, Shinohe Y, Ikeda J, Abe H. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses. Mol Carcinog 1997;18:171-176.
52. Nozaki M, Tada M, Matsumoto R, Sawamura Y, Abe H, Iggo RD. Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay. Acta Neuropathol (Berl) 1998;95:291-296.
53. Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, Shinohe Y. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res 1998;58:1793-1797.
54. Ishii N, Sawamura Y, Tada M, Daub DM, Janzer RC, Meagher-Villemure M, de Tribolet N, Van Meir EG. Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay. Int J Cancer 1998; 76:797-800.
55. Kashiwazaki H, Tonoki H, Tada M, Chiba I, Shindoh M, Totsuka Y, Iggo R, Moriuchi T. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene 1997;15: 2667-2674.
56. Guillou L, Estreicher A, Chaubert P, Hurlimann J, Kurt AM, Metthez G, Iggo R, Gray AC, Jichlinski P, Leisinger HJ, Benhattar T. Germ cell tumors of the testis overexpress wild-type p53. Am J Pathol 1996;149:1221-1228.
57. Martin A, Flaman JM, Frebourg T, Davi F, El Mansouri S, Amouroux J, Raphael M. Functional analysis of the p53 protein in AIDS-related non-Hodgkin's lymphomas and polymorphic lymphoproliferations. Br J Haematol 1998;101:311-317.
58. Mihara K, Miyazaki M, Kondo T, Fushimi K, Tsuji T, Inoue Y, Fukaya K, Ishioka C, Namba M. Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory. Acta Med Okayama 1997;51:261-265.
59. Goi K, Takagi M, Iwata S, Delia D, Asada M, Donghi R, Tsunematsu Y, Nakazawa S, Yamamoto H, Yokota J, Tamura K, Saeki Y, Utsunomiya J, Takahashi T, Ueda R, Ishioka C, Eguchi M, Kamata N, Mizutani S. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germline p53 mutation. Cancer Res 1997;57:1895-1902.
60. Varley JM, Chapman P, McGown G, Thorncroft M, White GRM, Greaves MJ, Scott D, Spreadborough A, Tricker KJ, Birch JM, Evans DGR, Reddel R, Camplejohn RS, Burn J, Boyle JM. Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family. Oncogene 1998;16:3291-3298.
61. Moshinsky DJ, Wogan GN. UV-induced mutagenesis of human p53 in a vector replicated in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 1997,94:2266-2271.
62. Inga A, Scott G, Monti P, Aprile A, Abbondandolo A, Burns PA, Fronza G. Ultraviolet-light induced p53 mutational spectrum in yeast is indistinguishable from p53 mutations in human skin cancer. Carcinogenesis 1998;9:741-746.
63. Inga A, Iannone R, Monti P, Molina F, Bolognesi M, Abbondandolo A, Iggo R, Fronza G. Determining mutational fingerprints at the human p53 locus with a yeast functional assay: a new tool for molecular epidemiology. Oncogene 1997;14:1307-1313.
64. Murata J, Tada M, Iggo RD, Sawamura Y, Shinohe Y, Abe H. Nitric oxide as a carcinogen: analysis by yeast functional assay of inactivating p53 mutations induced by nitric oxide. Mutat Res 1997;379:211-218.
65. Tada M, Sakuma S, Iggo RD, Saya H, Sawamura Y, Fujiwara T, Roth JA. Monitoring adenoviral p53 transduction efficiency by yeast functional assay. Gene Ther 1998;5:339-344.
66. Di Como CJ, Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 1998;16:2527-2539.
67. Brachmann RK, Vidai M, Boeke JD. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA 1996;93:4091-4095.
68. Barrack ER. Androgen receptor mutations in prostate cancer. Mt Sinai J Med (NY) 1996;63:403-412.
69. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi O-P. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998;152:1-9.